1. Clinical Overview
Etanercept is a recombinant human tumor necrosis factor (TNF) receptor fusion protein. It acts as a competitive inhibitor of TNF, a key pro-inflammatory cytokine involved in the pathogenesis of several autoimmune and inflammatory disorders. It is a biologic Disease-Modifying Anti-Rheumatic Drug (bDMARD) administered via subcutaneous injection.
| Onset | Duration | Bioavailability |
|---|---|---|
| Clinical improvement typically observed within 2-4 weeks, with maximum benefit often achieved by 3-6 months of continuous therapy. | The pharmacodynamic effect persists for the dosing interval (typically 1 week). Sustained clinical response requires regular administration. | Approximately 58-76% following subcutaneous administration. |
2. Mechanism of Action
Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It functions as a soluble decoy receptor. It competitively binds to both soluble and membrane-bound TNF-α and TNF-β, preventing their interaction with native TNF receptors (TNFR1 and TNFR2) on cell surfaces. This inhibits TNF-mediated cellular responses, including the release of pro-inflammatory cytokines (IL-1, IL-6), adhesion molecule expression, and neutrophil activation.
3. Indications & Uses
- Moderate to Severe Rheumatoid Arthritis (in combination with methotrexate or as monotherapy)
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Moderate to Severe Plaque Psoriasis (adult candidates for systemic therapy)
4. Dosage & Administration
Adult Dosage: 50 mg administered subcutaneously once weekly. For RA, PsA, and AS, some regimens may use 25 mg twice weekly or 50 mg once weekly; 50 mg once weekly is standard. For plaque psoriasis: 50 mg twice weekly for 3 months, followed by 50 mg once weekly.
Administration: For subcutaneous use only. Administer via pre-filled syringe or auto-injector. Rotate injection sites (thigh, abdomen, outer upper arm). Allow the prefilled syringe to reach room temperature (approx. 30 mins) before injection. Do not shake. Inspect for particulate matter or discoloration. Avoid areas that are tender, bruised, red, or hard. Proper training for self-administration is crucial.
5. Side Effects
Common side effects may include:
- Injection site reactions (erythema, itching, pain, swelling) - up to 37%
- Upper respiratory tract infections (sinusitis, pharyngitis)
- Headache
- Dizziness
- Rash
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Abatacept | Increased risk of serious infections; concomitant use not recommended. | Major |
| Anakinra | Increased risk of serious infections and neutropenia; concomitant use not recommended. | Major |
| Live Vaccines (BCG, MMR, Varicella, Zoster, Rotavirus, Yellow Fever) | Risk of disseminated vaccine-related infection. Avoid. | Major |
| Cyclophosphamide | Increased risk of malignancy; avoid concurrent use. | Major |
| Sulfasalazine | Potential increased risk of leukopenia; monitor CBC. | Moderate |
| Methotrexate | Concomitant use is common in RA. May slightly reduce clearance of etanercept. Monitor for additive immunosuppression. | Moderate |
| Warfarin | Case reports of altered INR; monitor INR closely upon initiation or discontinuation of etanercept. | Moderate |
7. Patient Counselling
- DO store the medication in a refrigerator (2°C to 8°C). Do not freeze.
- DO rotate injection sites with each dose.
- DO keep a medication diary to track injection dates and sites.
- DO complete all recommended vaccinations (non-live) before starting therapy, as per doctor's advice.
- DONT administer live vaccines while on etanercept.
- DONT share pens or syringes with another person.
- DONT inject into skin that is bruised, red, tender, or hard.
- DONT stop medication abruptly without consulting your doctor.
8. Toxicology & Storage
Overdose: Limited data. Single doses up to 62 mg have been administered without direct toxic effects. Potential effects may include severe immunosuppression and increased risk of serious infections.
Storage: Store in original carton to protect from light. Refrigerate at 2°C to 8°C. DO NOT FREEZE. Do not shake. If needed, the prefilled syringe/pen may be kept at room temperature (up to 25°C) for a single period of up to 14 days, after which it must be used or discarded. Protect from heat. Keep out of reach of children.